All patients received one cycle of Cytarabine and Daunorubicin (DA 3 + 7) as first induction therapy, some patients in combination with Gemtuzumab-Ozogamicin (GO) or Midostaurin because of CBF-AML (GO) or FLT-3 ITD/TKD (Midostaurin) mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.